Table 2.
Subjects with SARS-CoV-2 breakthrough infections following the mRNA-1273 booster and bivalent Omicron-adapted BNT162b2 vaccine.
| mRNA-1273 Booster | Bivalent Omicron-Adapted BNT162b2 | |||||
|---|---|---|---|---|---|---|
| SARS-CoV-2 breakthrough infection * | Yes N (%) |
No N (%) |
p-value ** | Yes N (%) |
No N (%) |
p-value ** |
| Yes | 157 (67) | 10 (83) | 0.347 | 26 (36) | 36 (39) | 0.683 |
| No | 79 (33) | 2 (17) | 47 (64) | 57 (61) | ||
* SARS-CoV-2 breakthrough infections were diagnosed as described in the Methods section (see text for details). ** Chi-squared test or Fisher’s exact test.